There are also technical bottlenecks which span the entire product development pipeline, and novel adjuvants are needed for vaccines for which conventional formulations have failed.
Samuti leidub praegu kogu tootearendusprotsessis tehnilisi kitsaskohti ning selleks, et toota vaktsiine, mille puhul tavapärased ravimikoostised ei toimi, on vaja uusi adjuvante.